News | May 27, 2021
Sun Pharma Q4 FY21 net profit up 124%
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
The company plans to enter the EU markets in FY22
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The company is working closely with its six manufacturing partners in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The company also plans to register the similar range of products in the neighbouring countries.
Subscribe To Our Newsletter & Stay Updated
